none11noThrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10–30% of cases after treatment tapering and discontinuation. Therefore, at least for selected responding patients, it might be rational to plan TPO-RA interruption to exploit off-treatment response. Intriguingly, complete or partial responses with TPO-RAs are frequently observed when treatments are initiated early, suggesting that unknown immune-related mechanisms may be involved in this phenomenon. The sustained responses observed after interruption of TPO-RAs may be interpreted as a recovery of immunologi...
The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary im...
Recent studies have indicated that medical options without splenectomy, such as rituximab (RTX) or t...
Identify patient experience and preference towards thrombopoietin-receptor agonists (TPO-RAs) in tre...
11noThrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of c...
24Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off-treatment (SROT...
International audienceSustained response off-treatment (SROT) after thrombopoietin receptor agonist ...
15noIntroduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids...
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). B...
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was r...
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clin...
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was r...
The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary im...
Recent studies have indicated that medical options without splenectomy, such as rituximab (RTX) or t...
Identify patient experience and preference towards thrombopoietin-receptor agonists (TPO-RAs) in tre...
11noThrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of c...
24Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off-treatment (SROT...
International audienceSustained response off-treatment (SROT) after thrombopoietin receptor agonist ...
15noIntroduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids...
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). B...
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was r...
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clin...
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was r...
The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patients with primary im...
Recent studies have indicated that medical options without splenectomy, such as rituximab (RTX) or t...
Identify patient experience and preference towards thrombopoietin-receptor agonists (TPO-RAs) in tre...